These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1980453)

  • 1. Treatment of NIDDM with insulin agonists or substitutes.
    Galloway JA
    Diabetes Care; 1990 Dec; 13(12):1209-39. PubMed ID: 1980453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
    Wolffenbuttel BH; van Haeften TW
    Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined insulin-sulfonylurea therapy in treatment of NIDDM.
    Groop LC; Groop PH; Stenman S
    Diabetes Care; 1990 Aug; 13 Suppl 3():47-52. PubMed ID: 2209344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin use in NIDDM.
    Genuth S
    Diabetes Care; 1990 Dec; 13(12):1240-64. PubMed ID: 2276309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of non-insulin-dependent diabetes mellitus with metformin.
    Guthrie R
    J Am Board Fam Pract; 1997; 10(3):213-21. PubMed ID: 9159660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
    Rachman J; Levy JC; Barrow BA; Manley SE; Turner RC
    Diabetes; 1997 Oct; 46(10):1557-62. PubMed ID: 9313749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea.
    Kabadi UM; Kabadi MU
    J Fam Pract; 1991 Oct; 33(4):349-53. PubMed ID: 1919450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin: either alone or combined with oral hypoglycemic agents.
    Firth RG
    Prim Care; 1988 Sep; 15(3):665-83. PubMed ID: 3054969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of conventional and intensified insulin therapy on free-insulin profiles and glycemic control in NIDDM.
    Lindström TH; Arnqvist HJ; von Schenck HH
    Diabetes Care; 1992 Jan; 15(1):27-34. PubMed ID: 1737539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination insulin-sulfonylurea therapy.
    Lebovitz HE; Pasmantier R
    Diabetes Care; 1990 Jun; 13(6):667-75. PubMed ID: 2192850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic treatment options for non-insulin-dependent diabetes mellitus.
    Tan GH; Nelson RL
    Mayo Clin Proc; 1996 Aug; 71(8):763-8. PubMed ID: 8691897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea.
    Dworacka M; Abramczyk M; Winiarska H; Kuczynski S; Borowska M; Szczawinska K
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):14-21. PubMed ID: 16425966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus.
    Prigeon RL; Jacobson RK; Porte D; Kahn SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3295-8. PubMed ID: 8784086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas.
    Reaven GM; Lardinois CK; Greenfield MS; Schwartz HC; Vreman HJ
    Diabetes Care; 1990 Aug; 13 Suppl 3():32-6. PubMed ID: 2209341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
    Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
    Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus.
    Gibson JM; Westwood M; Crosby SR; Gordon C; Holly JM; Fraser W; Anderson C; White A; Young RJ
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1369-75. PubMed ID: 7536208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are oral hypoglycemic agents likely to benefit NIDDM patients? Affirmative.
    Lebovitz HE
    Hosp Pract (Off Ed); 1992 Feb; 27 Suppl 1():26-31; discussion 35-6. PubMed ID: 1347536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.